Talk:Vidarabine
| This is the talk page for discussing improvements to the Vidarabine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Vidarabine.
|
The reference "McGuigan, C. Antiviral Chemotherapy – Cardiff University, 3rd Year Pharmacy Notes Lecture Notes." is not a reliable source and is unverifiable to anyone but McGuigan. Can someone find another references for these statements? --Selket Talk 23:38, 13 March 2007 (UTC)
These sentences: "This is where ara-ATP is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand.", especially the last part, is unclear and not very meaningful - if an ara base is incorporated, does that result in the DNA polymerase no longer recognizing the growing strand as a substrate, and therefore lead to strand termination? --Christina Jacobs, 68.80.179.147 (talk) 13:17, 11 August 2008 (UTC)
More toxic than intravenous Gancyclovir?
[edit]Is it really more toxic than Gancyclovir? At the end of the article, it says that side effects are rare and in most cases only occur after high doses. In Gancyclovir, side effects are not so rare. Chaptagai (talk) 22:48, 9 October 2017 (UTC)